Pancreatic Cancer Research

Clinical trialPhase 1 / Phase 2Completed

HCW9218 for Advanced Pancreatic Cancer

A Phase 1b/2 Study of HCW9218, a Bifunctional TGF-β (Transforming Growth Factor Beta) Antagonist/IL-15 (Interleukins) Protein Complex, for Advanced Pancreatic Cancer

Outcome
Finished, no results posted
Phase
Phase 1 / Phase 2
Status
Completed
Study type
Interventional
Start
17 October 2022
Ended
15 February 2025
Enrollment
21 participants
Sites
5
Primary outcomes
Occurrence of Adverse Events and Treatment-Related Adverse Events; Determine the maximum tolerated dose (MTD)
Sponsor type
Industry
Results posted
No
Last update
15 April 2026

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This is a Phase 1b/2, open-label, multi-center, competitive enrollment and dose-escalation study of HCW9218 in patients with advanced/metastatic pancreatic cancer.

Detailed description public domain (ClinicalTrials.gov)

The study involves a Phase 1b dose escalation portion with up to 30 patients to determine the MTD (maximum tolerated dose) using a 3+3 dose escalation design and to designate a dose level for the Phase 2 expansion phase (RP2D). The Phase 2 portion of the study will consist of an expansion cohort of up to 39 patients receiving HCW9218 monotherapy at the RP2D level. An additional independent Phase 2 cohort of patients receiving HCW9218 at the RP2D level in sequence with gemcitabine and nab-paclitaxel will also be considered.